Literature DB >> 23824485

The lifelong course of chronic epilepsy: the Chalfont experience.

Jan Novy1, Marco Belluzzo, Luís Otávio Caboclo, Claudia B Catarino, Mahinda Yogarajah, Lillian Martinian, Janet L Peacock, Gail S Bell, Matthias J Koepp, Maria Thom, Josemir W Sander, Sanjay M Sisodiya.   

Abstract

The long-term outcome of chronic epilepsy remains largely unknown, despite a long historical experience. We report the lifelong course of epilepsy of an historical cohort of 235 subjects who were in residential care at the Chalfont Centre for Epilepsy: 122 had comprehensive post-mortem examination. The populations admitted as resident to the centre over time followed the evolution of society's perception of epilepsy. 'Early residents' (before 1972) were admitted for sheltered employment, escaping stigmatization, whereas 'later' residents with more severe epilepsies were admitted for care. Subjects admitted before 1972 were similar to subjects followed nowadays as outpatients, whereas patients admitted later with a higher burden of disabilities are often those in residential care. This long follow-up allowed exploration of a wide spectrum of epilepsies, affecting both subjects who were otherwise healthy and those with co-morbidities. Age at death showed a bimodal distribution with an early peak of mortality between 45-50 years old, whilst the remainder had life expectancy comparable to the general population. As a group, subjects who had post-mortem examination were not significantly different from patients who did not have post-mortem examination, but post-mortem examination provided data that were otherwise unavailable. For those who had post-mortem examination, sudden unexpected death in epilepsy (SUDEP, 18% of all deaths) did not fully explain the early mortality, to which co-morbidities contributed. High seizure frequency was a significant independent predictor of early death even after excluding SUDEP (e.g. reduction in years of life for those who had >4 seizures/month compared with those who had <1 seizure/month: 13 years; 95% confidence interval: 6-19; overall P = 0.0006). Those who survived to older age increasingly went into spontaneous remission lasting until death (in the whole cohort, 38/166, 23% of those who died in or after sixth decade). In subjects who had post-mortem examination, older age (odds ratio = 1.13; 95% confidence interval: 1.06-1.20) and presence of neuropathologically confirmed degenerative changes (that were not the cause of epilepsy) (odds ratio 7.14; 1.95-26.2) were independent predictors of terminal remission. Epilepsy may cause premature death indirectly through co-morbid conditions. Terminal remission occurs even without prior remissions; ageing may improve epilepsy drug responsiveness although unknown factors related to the natural history may also play a role.

Entities:  

Keywords:  SUDEP; age; co-morbidities; drug-resistant epilepsy; mortality; remission

Mesh:

Year:  2013        PMID: 23824485     DOI: 10.1093/brain/awt117

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  11 in total

Review 1.  Review: The past, present and future challenges in epilepsy-related and sudden deaths and biobanking.

Authors:  M Thom; M Boldrini; E Bundock; M N Sheppard; O Devinsky
Journal:  Neuropathol Appl Neurobiol       Date:  2018-02       Impact factor: 8.090

2.  Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center.

Authors:  Lisa Langenbruch; Julia Krämer; Sati Güler; Gabriel Möddel; Sophia Geßner; Nico Melzer; Christian E Elger; Heinz Wiendl; Thomas Budde; Sven G Meuth; Stjepana Kovac
Journal:  J Neurol       Date:  2019-05-08       Impact factor: 4.849

Review 3.  Considering the Role of Extracellular Matrix Molecules, in Particular Reelin, in Granule Cell Dispersion Related to Temporal Lobe Epilepsy.

Authors:  Jennifer Leifeld; Eckart Förster; Gebhard Reiss; Mohammad I K Hamad
Journal:  Front Cell Dev Biol       Date:  2022-06-06

4.  The neurophysiology and seizure outcomes of late onset unexplained epilepsy.

Authors:  Rani A Sarkis; Louis Beers; Emile Farah; Mohammad Al-Akaidi; Yuxiang Zhang; Joseph J Locascio; Michael J Properzi; Aaron P Schultz; Jasmeer P Chhatwal; Keith A Johnson; Reisa A Sperling; Page B Pennell; Gad A Marshall
Journal:  Clin Neurophysiol       Date:  2020-09-19       Impact factor: 3.708

5.  Sudden unexpected death in epilepsy genetics: Molecular diagnostics and prevention.

Authors:  Alica M Goldman; Elijah R Behr; Christopher Semsarian; Richard D Bagnall; Sanjay Sisodiya; Paul N Cooper
Journal:  Epilepsia       Date:  2016-01       Impact factor: 5.864

Review 6.  Review: Hippocampal sclerosis in epilepsy: a neuropathology review.

Authors:  Maria Thom
Journal:  Neuropathol Appl Neurobiol       Date:  2014-08       Impact factor: 8.090

7.  Retinal nerve fibre layer thinning is associated with drug resistance in epilepsy.

Authors:  Simona Balestrini; Lisa M S Clayton; Ana P Bartmann; Krishna Chinthapalli; Jan Novy; Antonietta Coppola; Britta Wandschneider; William M Stern; James Acheson; Gail S Bell; Josemir W Sander; Sanjay M Sisodiya
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-17       Impact factor: 10.154

Review 8.  Recognizing and preventing epilepsy-related mortality: A call for action.

Authors:  Orrin Devinsky; Tanya Spruill; David Thurman; Daniel Friedman
Journal:  Neurology       Date:  2015-12-16       Impact factor: 9.910

9.  Audit of practice in sudden unexpected death in epilepsy (SUDEP) post mortems and neuropathological findings.

Authors:  Maria Thom; Zuzanna Michalak; Gabriella Wright; Timothy Dawson; David Hilton; Abhijit Joshi; Beate Diehl; Matthias Koepp; Samden Lhatoo; Josemir W Sander; Sanjay M Sisodiya
Journal:  Neuropathol Appl Neurobiol       Date:  2015-09-25       Impact factor: 8.090

10.  SAD-B modulates epileptic seizure by regulating AMPA receptors in patients with temporal lobe epilepsy and in the PTZ-induced epileptic model.

Authors:  Rong Li; Miaoqing He; Bing Wu; Peng Zhang; Qinbin Zhang; Yangmei Chen
Journal:  Braz J Med Biol Res       Date:  2020-04-06       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.